Hello Dave,
Thank you for the feedback.
Please see below screenshot of the first paragraph under heading “TGA Registration Plan” on page 2 from EMD announcement dated 5 Jan 2021.
”To date, only 1 cannabinoid-based medicine has been formally registered with the TGA - GW Pharma’s, Epidyolex - a CBD-only medicine for the “adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS)”(5). All other cannabinoid-based medicines are available only via Special Access Schemes, Authorised Prescribers or clinical trials.”
EMD Research, page-11
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.87M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 58823 | 3.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.3¢ | 2481 | 1 |
View Market Depth
| Last trade - 11.08am 01/11/2024 (20 minute delay) ? |
| EMD (ASX) Chart |
Day chart unavailable